EGFR and lung adenocarcinoma: Osimertinib, a third-generation EGFR TKI, targets mutant EGFR harboring both TKI-sensitizing and first/second-generation EGFR TKI-resistant T790M mutation in lung adenocarcinoma patients [2,3].